Clinical trial · Observational
Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): More critical projects were prioritized.
Summary
Brief summary (as posted)
While there are many medical options for managing endometriosis and fibroids, GnRH-agonist (GnRH-a) therapy remains a very common method of treating these complex conditions. Although this therapy is effective, it does come with significant menopausal side effects, such as hot flashes, sweating, mood changes, sleep disturbance, altered sex drive, decreased bone density, and vaginal and urinary symptoms. In short, chemically-induced menopause (menopause triggered by GnRH-a injection) causes the same symptoms of natural menopause, but with a sudden onset in a generally young and active population. Low dose hormone add-back therapy is commonly used to lessen these side effects of GnRH-a use. There are many menopausal hormone therapies (MHTs) used in menopausal women that can help, but few studies have directly evaluated the different options of treatment for women undergoing chemically-induced menopause. Tibolone is a menopausal hormone therapy (MHT) that stands out as a good option in the management of medical menopause in endometriosis patients because it may give fewer side effects than other alternatives and have a positive effect on mood and libido. This study aims to see how effective Tibolone is as an add-back therapy in women who are hormonally suppressed with a GnRH-a. For this study, we will recruit pre-menopausal women over the age of 18 years old undergoing therapy with the GnRH-a Lupron.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometriosis | — | UNRESOLVED | — |
| Fibroids | Leiomyoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tibolone 2.5 Mg Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pre-menopausal women >18 years old with endometriosis and/or uterine fibroids
- description
- GnRH-a depot (11.25mg IM x 1) and daily Tibolone 2.5mg orally once a day for 2-3 months.
- interventionNames
- Drug: Tibolone 2.5 Mg Oral Tablet
Primary outcomes (8)
- measure
- Patient reported relief of menopausal symptoms
- timeFrame
- Baseline
- description
- Patient reported relief of menopausal symptoms will be evaluated using the Menopause rating scale (MRS). The MRS is a validated 11-item health-related quality of life scale (HRQoL), that measures the presence and severity of menopausal symptoms.
- measure
- Patient reported relief of menopausal symptoms
- timeFrame
- 1 month following injection
- description
- Patient reported relief of menopausal symptoms will be evaluated using the Menopause rating scale (MRS). The MRS is a validated 11-item health-related quality of life scale (HRQoL), that measures the presence and severity of menopausal symptoms.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pre-menopausal woman over 18 years of age with known or suspected endometriosis and/or uterine fibroids * Undergoing medical management of endometriosis with a depot injection of GnRH-a for 3 months * Off all other hormonal medications for the period of this treatment * With or without history of recent hormonal treatment for endometriosis * Able to provide informed consent Exclusion Criteria: * Allergy or contraindication to GnRH-a therapy, tibolone, or any contraindications to estrogen or progestin replacement * Any uncontrolled endocrinopathy (ex: Pituitary gland disorder, uncontrolled hypothyroidism, etc) * Prior hysterectomy * Menopausal status * Pregnant or seeking pregnancy
References
Publications (0)
Data not yet available